Spago Nanomedical: Tumorad-01 advances and the study is now ready to include the next patient cohort - Redeye

The independent Data Monitoring Committee (DMC) recommends to proceed the clinical Tumorad-01, with inclusion of patients with different tumor types. This green light follows as the first three treated patients in the study shows a satisfactory safety profile. The next DMC meeting will follow once three additional patients have completed the first treatment cycle.

Länk till analysen i sin helhet: https://www.redeye.se/research/1035249/spago-nanomedical-tumorad-01-advances-and-the-study-is-now-ready-to-include-the-next-patient-cohort?utm_source=finwire&utm_medium=RSS